EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 20 / No 10 (Octobre 2004) Med Sci (Paris), 20 10 (2004) 929-932 References
Free Access
Issue
Med Sci (Paris)
Volume 20, Number 10, Octobre 2004
Page(s) 929 - 932
Section Forum
DOI https://doi.org/10.1051/medsci/20042010929
Published online 15 October 2004
  1. Scriver CR, Kaufman S. Hyperphenlylalaninemia : phenylalanine hydroxylase deficiency. In : Scriver CR, Baudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease, chapter 77. New York : McGraw Hill, 2001 : 1671. [Google Scholar]
  2. Abadie V, Rey F, Plainguet F, Rey J. Évolution intellectuelle après relâchement du régime à l’âge de 5 ans dans la phénylcétonurie typique. Arch Fr Pediatr 1992; 49 : 773–8. [Google Scholar]
  3. Burgard P, Schmidt E, Rupp A, et al. Intellectual development of the patients of the German collaborative study of children treated for phenylketonuria. Eur J Pediatr 1996; 155 (suppl 1) : S33–8. [Google Scholar]
  4. Hommes FA. Loss of neurotransmitter receptors by hyperphenylalaninemia in the HPH-5 mouse brain. Acta Paediatr 1992; 907 (suppl) : 120–1. [Google Scholar]
  5. Meli C, Garozzo R, Mollica F, et al. Different clinical manifestations in siblings with identical phenylalanine hydroxylase genes mutations. J Inher Metab Dis 1998; 21 (suppl 2) : 10. [Google Scholar]
  6. Gizewska M, Zekanowski C, Cyriowski L, et al. Different presentation of late-detected PKU in two brothers with the same R408W/R111X mutations in PAH gene. J Inher Metab Dis 2001; 24 (suppl 1) : 22. [Google Scholar]
  7. Jepson JB, Lovenberg W, Zaltzman P, et al. Conversion of phenylalanine to phenylethylamine in patients with phenylketonuria. Biochem J 1960; 74 : 5. [Google Scholar]
  8. Oates JA, Nirenberg PZ, Jepson JB, et al. Amine metabolism, studied in normal and phenylketonuric humans by monoamine oxydase inhibition. Proc Soc Exp Biol Med 1963; 112 : 1078–81. [Google Scholar]
  9. Michals K, Matalon R. Phenylalanine metabolites, attention span and hyperactivity. Am J Clin Nutr 1985; 42 : 361–5. [Google Scholar]
  10. Paterson IA, Juorio AV, Boulton AA. 2-Phenylethylamine : a modulator of catecholamine transmission in the mammalian central nervous system ? J Neurochem 1990; 55 : 1827–37. [Google Scholar]
  11. Blau K. The significance of phenylethylamine in phenylketonuria and related disorders. In : Mosnaïm AD, Wolf ME, eds. Noncatecholic phenylethylamines. Part I. Phenylethylamine : biological mechanisms and clinical aspects. New York : Marcel Dekker, 1978 : 385–96. [Google Scholar]
  12. Loo YH, Jervis GA, Horning MG. Possible role of 2-phenylethylamine in the pathology of the central nervous system. In : Mosnaïm AD, Wolf ME, eds. Noncatecholic phenylethylamines. Part I. Phenylethylamine : biological mechanisms and clinical aspects. New York : Marcel Dekker, 1978 : 419–45. [Google Scholar]
  13. Denno KM, Sadler TW. Phenylalanine and its metabolites induce embryopathies in mouse embryos in cultures. Teratology1990; 42 : 565–70. [Google Scholar]
  14. Johnston JP. Some observations upon a new inhibitor of monoamine oxydase in brain tissues. Biochem Pharmacol1968; 17 : 1285–97. [Google Scholar]
  15. Lewinsohn R, Glover V, Sandler M. Development of benzylamine oxidase and monoamine oxydase A and B in man. Biochem Pharmacol 1980; 29 : 1221–30. [Google Scholar]
  16. Cases O, Vitalis T, Seif I, et al. Lack of barrels in the somatosensory cortex of monoamine oxydase A-deficient mice : role of serotonin excess during the critical period. Neuron 1996; 16 : 297–307. [Google Scholar]
  17. Donnelly E, Murphy DL, Waldman IN, et al. Psychological characteristics corresponding to low versus high platelet monamine oxydase activity. Biol Psychiatr 1979; 14 : 375–83. [Google Scholar]
  18. Mellick GD, Buchanan DD, Mc Cann SJ, et al. Variations in the monoamine oxydase B (MAOB) gene are associated with Parkinson’s disease. Mov Disord 1999; 14 : 219–24. [Google Scholar]
  19. Carrasco JL, Diaz-Marsa M, Hollander E, et al. Decreased platelet monoamine oxydase activity in female bulimia nervosa. Eur Neuropsychopharmacol 2000; 10 : 113–7. [Google Scholar]
  20. Wahlund B, Saaf J, Wetterberg L. Clinical symptoms and platelet monoamine oxydase in subgroups and different states of affective disorders. J Affect Disord 1995; 35 : 75–87. [Google Scholar]
  21. Verkes RJ, Pijl H, Meinders AE, Van Kempen GM. Borderline personality, impulsiveness and platelet monoamine oxydase in bulimia nervosa and recurrent suicidal behavior. Biol Psychiatr 1996; 40 : 173–80. [Google Scholar]
  22. Fowler JS. Inhibition of monoamine oxydase B in the brain of smokers. Nature 1996; 379 : 733–6. [Google Scholar]
  23. Spada M, Vigliano P, Battistoni G, et al. Monoamine oxydase inhibitors in phenylketonuria. J Inher Metab Dis 1998; 21 (suppl 2) : 11. [Google Scholar]
  24. Shih JC, Chen K, Ridd MJ. Monoamine oxydase : from genes to behavior. Ann Rev Neurosci 1999; 22 : 197–217. [Google Scholar]
  25. Grimsby J, Toth M, Chen K, et al. Increased stress response and phenylethylamine in MAOB-deficient mice. Nat Genet 1997; 17 : 206–10. [Google Scholar]
  26. Lenders JW, Eisenhofer G, Abeling NG, et al. Specific deficiencies of the MAOA and B isoenzymes of monoamine oxydase are characterized by distinct neurochemical and clinical phenotypes. J Clin Invest 1996; 97 : 1010–9. [Google Scholar]
  27. Collins FA, Murphy DL, Reiss AL, et al. Clinical, biochemical, and neuropsychiatric evaluation of a patient with a contiguous gene syndrome due to a microdeletion Xp11.3 including the Norrie disease locus and monoamine (MAOA and MAOB) genes. Am J Med Genet 1992; 42 : 127–34. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.